https://www.economist.com/finance-and-economics/2025/02/26/how-cheap-can-investing-get
expenses of .03% v .09%
in praise of vanilla economist
https://www.economist.com/finance-and-economics/2025/02/26/how-cheap-can-investing-get
expenses of .03% v .09%
in praise of vanilla economist
from the Burgess Shale
https://www.nytimes.com/2025/02/18/science/asteroid-2024-yr4-impact.html
Will That Asteroid Strike Earth? Risk Level Rises to Highest Ever Recorded.
The threat from space rock 2024 YR4 has surpassed that of Apophis, an asteroid feared by scientists 20 years ago. The danger remains low, but experts are estimating the damage that could be done.
Feb. 18, 2025
Astronomers on Tuesday said that the asteroid designated 2024 YR4 had become the most likely sizable space rock ever forecast to impact planet Earth. The object, first detected in December, is 130 to 300 feet long and expected to make a very close pass of the planet in 2032. Its odds of impacting Earth on Dec. 22 of that year currently stand at 3.1 percent….
adenosine by awake for sleep, cortisol in morning for wake, melatonin by dark for sleep
sleep=N1,N2,N3,REM
QT:{{”
Richard – Absolutely correct. That’s exactly what we did. We designed a study using a treatment called benralizumab. Benralizumab is an antibody therapy given by injection which specifically targets eosinophil production and migration into the lungs. We compared this with standard therapy oral corticosteroids, and indeed we had a third arm, which was a combination of the two treatments together. “}}
https://www.nature.com/articles/d41586-024-03866-5
QT:{{”
One particular gut microbe is quite the coffee fiend. Lawsonibacter asaccharolyticus was up to eight times more abundant in coffee drinkers than in non-drinkers. In a culture dish, the bacteria grew faster when fed coffee of any kind — brewed or instant, caffeinated or decaffeinated — than when fed no coffee.
“}}
https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza glp-1 agonists
QT:{{”
The drugs’ biggest impact so far, though, has been on their makers. Sales of Wegovy, developed by a Danish firm called Novo Nordisk, swelled from $876m in 2022 to $4.5bn in 2023. The company expects double that this year. Zepbound, introduced in America in November by Eli Lilly, an American pharma giant, is expected to generate $2.9bn in sales in its first full year. Bloomberg, a data provider, predicts that by 2030 yearly sales of weight-loss medications will reach a staggering $80bn, putting them among the biggest classes of drugs in history. Eli Lilly and Novo Nordisk are expected to corner more than 90% of the market (see chart 2).
“}}